Clinical Trials & Translational Studies in Scleroderma


Actively Recruiting Clinical Trials

Study Name


Principal Investigator

Study Contact


Rilonacept- Randomized, Double-Blind,
Placebo-Controlled Trial of IL1-TRAP –
A Phase I/II Biomarker Trial
Diffuse SSc Robert Lafyatis, MD Jessica Ziemek


LOTUSS Study – Pirfenidone in
Interstitial Lung Disease
Diffuse & Limited


Robert Simms, MD Britte Zlatanova

Kim Finch

Fei-Ying Cheong


Quantification of Septal Thickening in
Scleroderma Patients Utilizing Hyperpolarized
129Xe MRI
SSc with ILD Robert Lafyatis Fei-Ying Cheong


Pomalidomide in Diffuse SSc with ILD Diffuse SSc with ILD Robert Simms, MD Eric Stratton

Fei-Ying Cheong

A Randomized, Double-Blind, Placebo-
Controlled, Phase II Multi-Center Trial of a
Monoclonal Antibody to CD20 (Rituxamab)
For the Treatment of Systemic Sclerosis-
Associated Pulmonary Arterial Hypertension
Harrison Farber, MD

Robert Simms, MD

Eric Stratton

Fei-Ying Cheong
IKARIA A Phase 2,
Placebo Controlled,
Double-Blind, Randomized, Clinical
Study To Determine Safety,Tolerability
and Efficacy of Pulsed, Inhaled Nitric
Oxide (iNO) Versus Placebo As Add-On
Therapy in Symptomatic Subjects with
Pulmonary Arterial Hypertension (PAH)
PAH Harrison Farber, MD Fei-Ying Cheong


SYMPHONY- A Multi-center, Open Label,
Single-arm, Phase 3b Study of
Macitentan in Patients with
Pulmonary Arterial Hypertension
to psychometrically validate the
PAH-SYMPACT instrument
PAH Harrison Farber, MD Kim Finch


Actively Recruiting Translational Studies

Fibroblast and Immune Cell
Culture From Skin
Diffuse SSc Robert Lafyatis, MD Jessica Ziemek


CORT Biomarker Study SSc Robert Lafyatis, MD Eric Stratton